Binx Health said the initial distribution of its platform will be to settings certified to perform moderate- or high-complexity diagnostic tests under CLIA.
The Applied Biosystems TaqPath COVID-19, Flu A, Flu B Combo Kit can detect and differentiate RNA from SARS-CoV-2, influenza A, and influenza B viruses.
The kit, developed by Gauss in collaboration with Cellex, uses a smartphone app to instruct an individual on how to collect a sample and perform the test.
Fluidigm CEO Chris Linthwaite said the company aims to further penetrate the diagnostic and clinical markets with both its microfluidics and mass cytometry businesses.
Investors reacted favorably to a report Wednesday evening saying the Carlsbad, California-based firm is working with a financial advisor on a potential sale.
The company said the study will evaluate the ability of its Reveal System to detect and characterize antimicrobial resistance of Gram-negative bacteremia samples.
The firm also announced a COVID-19 testing deal with George Mason University and a CyTOF supply and distribution agreement with Zhejiang PuLuoTing Health Technology in China.
The firm's CEO said that the deprioritization of its submission for a standalone SARS-CoV-2 assay running on its Verigene I molecular diagnostic instrument is puzzling.
The company said the money, which includes seed funding from Novalis Biotech, will be used in part to support the development of a saliva-based SARS-CoV-2 antigen test.
During laboratory validation, the test showed sensitivity against high viral loads of 97.1 percent and specificity of 99.9 percent, the UK government said.
